Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Trial Profile

Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Autoimmune disorders; Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Octapharma
  • Most Recent Events

    • 25 Jan 2017 Planned number of patients changed from 2000 to 5000.
    • 25 Jan 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
    • 16 Feb 2016 Planned End Date changed from 31 Dec 2015 to 31 Dec 2017, according to ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top